| Publications :: | Assistant
Professor of Pediatrics Division of Pediatric Endocrinology and Metabolism 
Dr. Pedro Velasquez-Mieyer is part of a team studying the health impact
of the epidemic of obesity and type 2 diabetes mellitus among children
in the mid-south area. He has concentrated his research efforts on
identifying possible mechanisms involved in the genesis of obesity
and related conditions and the potential influence of racial and lifestyle
factors to predict treatment outcomes. To increase understanding of
the natural history of obesity and associated co-morbidities, he has
been directly involved in the follow-up of cohorts of pediatric and
adult subjects with these conditions during the last several years. In both
children and adults, he is evaluating the role of insulin and GLP-1
in the etiology and pathogenesis of obesity, diabetes, cardiovascular
disease and other associated complications. |
| Velasquez-Mieyer PA, Umpierez
GE, Lustig RH, Cashion AK, Cowan PA, Burghen GA. Racial differences
in glucagon-like peptide (GLP-1) concentrations and insulin dynamics
during oral glucose tolerance test in obese subjects. Int
J Obes 2003; 27:1359-1364. Velasquez-Mieyer, PA, Umpierrez, GE, Lustig, RH, Cashion, AK, Cowan, PA, Christensen, Spencer, KA and Burghen, GA: Race affects insulin and GLP-1 secretion and response to a long-act-ing somatostin analogue in obese adults. Int J Obesity 2004; 28: 330-333. Mallare JT, Karabell AH, Velasquez-Mieyer PA, Stender S, Christensen ML. Current and future treatment of metabolic syndrome and type 2 diabetes in children and adolescents. Diabetes Spectr 2005; 18: 220-228. Velasquez-Mieyer PA, Perez-Faustinelli S, Cowan PA. Identifying children at risk for obesity, type 2 diabetes and cardiovascular disease. Diabetes Spectr 2005 18:213-220. Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV. Single and multiple dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol 2005; 45(10):1137-1144. Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W , Hohneker J. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006;30(2):331-341. Lustig RH, Mietus-Snyder ML, Bacchetti P, Lazar AA, Velasquez-Mieyer PA, Christensen ML. Insulin dynamics predict response to insulin suppression or sensitization pharmacotherapy in obese children. J Pediatr 2006; 148(1):23-29. |